NCT07612098 Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma Status NOT_YET_RECRUITING Phase PHASE2
NCT07540390 GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. Status NOT_YET_RECRUITING Phase PHASE3
NCT07538271 A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT07538258 Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT07537777 Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy Status NOT_YET_RECRUITING Phase PHASE2
NCT07470840 SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Status NOT_YET_RECRUITING Phase PHASE2
NCT07443397 Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. Status RECRUITING Phase PHASE3
NCT07388875 Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC Status NOT_YET_RECRUITING Phase PHASE2
NCT07376499 Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction Status NOT_YET_RECRUITING Phase PHASE2
NCT07330544 A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy Status RECRUITING Phase PHASE2
NCT07320963 Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT07172412 Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT07037680 Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT Status RECRUITING Phase PHASE2
NCT07025174 Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer Status RECRUITING Phase PHASE2
NCT07010393 Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study Status NOT_YET_RECRUITING Phase PHASE4
NCT06970145 Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma Status RECRUITING Phase PHASE1/PHASE2
NCT06951841 Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction Status NOT_YET_RECRUITING Phase PHASE4
NCT06931145 Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer Status NOT_YET_RECRUITING Phase PHASE4
NCT06851247 GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma. Status RECRUITING Phase PHASE2
NCT06761417 A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults Status RECRUITING Phase PHASE2